Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

ISRCTN ISRCTN74348595
DOI https://doi.org/10.1186/ISRCTN74348595
ClinicalTrials.gov number NCT00124072
Secondary identifying numbers CTSU SEARCH1
Submission date
15/08/2005
Registration date
09/09/2005
Last edited
31/08/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Prof Rory Collins
Scientific

Clinical Trial Service Unit
Richard Doll Building
Old Road Campus
Oxford
OX3 7LF
United Kingdom

Phone +44 (0)1865 743743
Email Secretary@ctsu.ox.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific titleStudy of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
Study acronymSEARCH
Study hypothesisDo larger reductions in blood cholesterol produce larger, and worthwhile, reductions in cardiovascular risk, and does homocysteine-lowering with folic acid and vitamin B12 reduce cardiovascular risk?
Ethics approval(s)Not provided at time of registration
ConditionCoronary heart disease
InterventionSimvastatin 80 mg versus 20 mg daily, and separately folic acid 2 mg plus 1 mg vitamin B12 daily or matching placebo tablets.
Intervention typeSupplement
Primary outcome measureMajor vascular events (MVEs) during the scheduled treatment period
Secondary outcome measuresMVEs separately during the first year and in the later years of the study, MVEs in patients subdivided by pre-randomisation lipid levels, MVEs in the presence and absence of the other randomised treatments, major coronary events, total strokes
Overall study start date30/07/1998
Overall study end date31/12/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants12,064
Total final enrolment12064
Participant inclusion criteriaMen and women who have survivied a heart attack and in whom statin therapy is indicated.
Participant exclusion criteriaAge under 18 years or over 80 at invitation, contraindications to either study drug, other predominant medical problem.
Recruitment start date30/07/1998
Recruitment end date31/12/2007

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Clinical Trial Service Unit
Oxford
OX3 7LF
United Kingdom

Sponsor information

University of Oxford (UK)
University/education

University Offices
Wellington Square
Oxford
OX1 2JD
England
United Kingdom

Phone +44 (0)1865 270000
Email search@ctsu.ox.ac.uk
Website http://www.ox.ac.uk
ROR logo "ROR" https://ror.org/052gg0110

Funders

Funder type

Industry

A grant to Oxford University from Merck and Co.

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 21/08/2008 Yes No
Results article results 23/06/2010 Yes No
Basic results 26/09/2019 No No

Editorial Notes

31/08/2022: A long-term follow-up study of SEARCH has been registered as ISRCTN14416153.
26/09/2019: The following changes were made to the trial record:
1. Added ClinicalTrials.gov link to basic results (scientific).
2. The total final enrollment was added.
3. ClinicalTrials.gov number added.